Contact FutureLearn for Support
Skip main navigation
We use cookies to give you a better experience, if that’s ok you can close this message and carry on browsing. For more info read our cookies policy.
We use cookies to give you a better experience. Carry on browsing if you're happy with this, or read our cookies policy for more information.

Challenges of array CGH interpretation in clinical practice

The introduction of any new technology into routine clinical practice brings with the benefits new challenges that need to be addressed but also that may not have been anticipated.

The purpose of array CGH analysis is to report only those findings that definitely explain or are highly likely to explain the presenting symptoms and signs of the patient. However other scenarios may arise.

  • CNV of uncertain significance

    Due to the high resolution of the test we may identify copy number variations (CNV) of uncertain significance. The challenge here is prepare patients and their families in advance that we may find CNV(s) of uncertain clinical significance but that this is an evolving field and we are constantly learning about the degree of genetic variation in humans such that our interpretation of such CNVs may change in the future and that they will be contacted if appropriate. This uncertainty can cause anxiety for patients and families thus counselling them in advance of this potential outcome is important.

  • CNV of variable penetrance

    Array CGH has revealed that there exist a significant number of neurosusceptibility loci (regions) that lower the threshold for manifesting intellectual difficulties, autistic spectrum disorder, and developmental delay. When identified in a child presenting with such symptoms one of the parents is often found to carry the same CNV but does not have a history of symptoms. This is known as reduced penetrance and it is presumed that additional factors are required to cause the symptoms to manifest.

  • Incidental findings

    Infrequently, the testing may identify a clinically significant deletion or duplication that is not the cause for the presenting symptoms in the patient but may have implications for their future health and, if inherited, for the health of their relatives. An example of this would be deletion of a cancer predisposition gene. Such results are fed back to patients so that they can be counselled about screening programmes or prophylactic surgery.

Despite some of these difficulties, for those of us in the practice of clinical genetics and paediatrics, this test has allowed us to give many more families an explanation for their child’s difficulties. Although curative treatment may not be possible this allows us to give information on the natural history of the condition to the family which can be “therapeutic” and assists in devising a management and educational strategy to support the child’s growth and development.

Share this article:

This article is from the free online course:

The Genomics Era: the Future of Genetics in Medicine

St George's, University of London

Course highlights Get a taste of this course before you join:

  • Welcome to Week 1
    Welcome to Week 1

    In this video, Lead Educator, Dr Kate Tatton-Brown welcomes learners to the course and explains the course aims and outcomes.

  • Did you know?
    Did you know?

    Our resident scientist tells you his favourite genomics facts.

  • Errors in recombination
    Errors in recombination

    This video describes how structural chromosome abnormalities occur when errors occur in recombination.

  • Responsibility in the genomic era
    Responsibility in the genomic era

    In this tutorial, you will hear from Dr Carwyn Rhys Hooper on the concept of responsibility for health.